Effect of weekly versus daily primaquine on Plasmodium vivax malaria recurrences: A real-life cohort study

BACKGROUND: Although primaquine (PQ) is indicated for G6PD-deficient patients, data on weekly PQ use in Brazil are limited. METHODS: We aimed to investigate malaria recurrences among participants receiving daily and weekly PQ treatments in a real-life setting of two municipalities in the Amazon betw...

Descripción completa

Detalles Bibliográficos
Autores principales: Brito-Sousa, Jose Diego, Phanor, Jeffe, Balieiro, Patricia Carvalho da Silva, Silva-Neto, Alexandre Vilhena, Cordeiro, Jady Shayenne Mota, Vitor-Silva, Sheila, Mendes, Maxwell, Sampaio, Vanderson Souza, de Melo, Gisely Cardoso, Lacerda, Marcus, Monteiro, Wuelton
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Sociedade Brasileira de Medicina Tropical - SBMT 2022
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9070075/
https://www.ncbi.nlm.nih.gov/pubmed/35522815
http://dx.doi.org/10.1590/0037-8682-0738-2021
Descripción
Sumario:BACKGROUND: Although primaquine (PQ) is indicated for G6PD-deficient patients, data on weekly PQ use in Brazil are limited. METHODS: We aimed to investigate malaria recurrences among participants receiving daily and weekly PQ treatments in a real-life setting of two municipalities in the Amazon between 2019 and 2020. RESULTS: Patients receiving weekly PQ treatment had a lower risk of recurrence than those receiving daily PQ treatment (risk ratio: 0.62, 95% confidence interval: 0.41-0.94), using a model adjusted for study site. CONCLUSIONS: Weekly PQ use did not increase the risk of malaria recurrence. Further studies with larger populations are warranted.

Ejemplares similares